FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
FibroGen, Inc (FGEN)
Last fibrogen, inc earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=253783&p=irol-irhome
Company Research
Source: GlobeNewswire
• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) expected in 1Q 2024 • FibroGen regains rights to roxadustat from AstraZeneca in the United States and other AstraZeneca territories, except China and South Korea • FY 2023 total net revenue of $147.8 million, an increase of 5% year over year • Robust roxadustat volume growth of 41% in China in FY 2023 compared to FY 2022 • Successful execution of cost reduction plan; $248.1 million in cash provides cash runway into 2026 SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2023 and provided an update on the company’s recent developments. “We are extremely excited about the company’s prospects in 2024,” said Thane Wettig, Chief Executive Officer, FibroGen. “In this year
Show less
Read more
Impact Snapshot
Event Time:
FGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FGEN alerts
High impacting FibroGen, Inc news events
Weekly update
A roundup of the hottest topics
FGEN
News
- FibroGen Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- FibroGen Reports First Quarter 2024 Financial ResultsGlobeNewswire
- Global Duchenne Muscular Dystrophy Drugs Market Set to Reach $ 5.5 Billion by 2032, With a CAGR of 10.17% Driven by New Product Approvals, Launches, and a Favorable Landscape [Yahoo! Finance]Yahoo! Finance
- FibroGen to Report First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- FibroGen to Report First Quarter 2024 Financial ResultsGlobeNewswire
FGEN
Earnings
- 5/6/24 - Miss
FGEN
Sec Filings
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- 5/2/24 - Form 4
- FGEN's page on the SEC website